Company Active LTD

Company profile

Mint Diagnostics Ltd

Hormonix

Mint Diagnostics Ltd is a UK company with status active founded in 2016 based in East of England.

CRN
10212145
Founded
2016
Age
10

Overview

Legal name
MINT DIAGNOSTICS LTD
Region
East of England
Registered address
C/O PEM SALISBURY HOUSE
STATION ROAD
CAMBRIDGE
CAMBRIDGESHIRE
CB1 2LA
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Mint Diagnostics Ltd
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

6 events
12 Sep
2024

Liquidation Voluntary Statement Of Receipts And Payments With Brought Down Date

Insolvency

LIQ03 | Transaction MzQzNDY0OTI3OWFkaXF6a2N4 | Paper/PDF filed

Published 13 Sep 2024 12:48

31 Mar
2024

Accounts due

Accounts Due

Next accounts due date

02 Feb
2024

Confirmation statement due

Confirmation Due

Next confirmation statement due date

19 Jan
2023

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2022

Accounts filed

Accounts

Last accounts made up date

02 Jun
2016

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2017
Funded years
2017, 2019, 2020, 2021
Age at first award
0 years

Projects

2021 Collaborative R&D Lead participant

Development and Manufacturing of salivary Point-of-Care tests

1 Apr 2021 to 30 Sep 2022

Awarded
£690,000
Total cost £692,080

Hormone levels impact countless aspects of daily life, from mood and tiredness, to sporting performance, and medical treatment efficacy. Mint Diagnostics has made significant progress in developing Hormonix, our point-of-care diagnostics system for monitoring steroid hormones in saliva, for human performance optimisation and personalised healthcare. This ...

2020 Study Lead participant

Hormonix: fully automated low-cost salivary hormone monitoring

1 Nov 2020 to 30 Apr 2022

Awarded
£324,338
Total cost £463,340

Mint Diagnostics is redefining how data on hormone levels can be monitored and used to improve human performance. Combining our proprietary salivary testing and analysis technology with advanced data interpretation, we enable precise monitoring of performance within a variety of contexts, from elite sports to health and wellness. Our project is supported ...

2019 Feasibility Studies Lead participant

Mobile hormone monitoring platform for cancer management

1 May 2019 to 31 Jan 2020

Awarded
£52,331
Total cost £74,759

We will assess the market and technical feasibility of a new companion device for cancer treatment and management. The technology will enable clinicians to monitor the hormone levels of their patients in real-time, and from such information it will be possible to precisely optimise treatments and management programmes.

2017 Feasibility Studies Lead participant

Point-of-care diagnostics for stress monitoring based on graphene-aptamer technology

1 May 2017 to 31 Dec 2017

Awarded
£68,250
Total cost £97,500

We combine the two emerging technologies of graphene and aptamers to realise a portable personal device for monitoring stress levels. The product offers a 'personal anti-stress coach' service, via a combination of biosensing functionalities and data interpretation, with a dedicated mobile application and a user-centric design. The product goes beyond the ...

Product types

Collaborative R&D Feasibility Studies Study